title: The development and use of the E75 (HER2 369-377) peptide vaccine.
abstract: E75 (nelipepimut-S) is an immunogenic peptide derived from the HER2 protein. When combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), nelipepimut-S has been used as a vaccine that is capable of eliciting a robust anti-HER2 immune response. Early-phase clinical trials that enrolled women with node-positive or high-risk node-negative breast cancer who had been rendered disease free with standard of care therapy but were at risk for recurrence, demonstrated the vaccine to be safe with a suggestion of clinical benefit. Nelipepimut-S is currently being evaluated in a Phase III clinical trial. This article covers the preclinical and clinical development of nelipepimut-S.
authors.affiliation: Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, Houston, TX 77030, USA.
authors.forename: Guy T
authors.initials: GT
authors.lastname: Clifton
authors.affiliation: Cancer Vaccine Development Program, Metis Foundation, 600 Navarro Street, San Antonio, TX 78205, USA.
authors.forename: George E
authors.initials: GE
authors.lastname: Peoples
authors.affiliation: Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1434, Houston, TX 77030, USA.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Mittendorf
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000628:therapy*; D019496:Cancer Vaccines / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D015195:Drug Design; D005260:Female; D006801:Humans; D010446:Peptide Fragments / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology* / Q000494:pharmacology; D022223:Vaccines, Subunit / Q000494:pharmacology
chemical_list: D019496:Cancer Vaccines; D010446:Peptide Fragments; D018719:Erb-b2 Receptor Tyrosine Kinases; D022223:Vaccines, Subunit; C561872:HER2 peptide (369-377)
keywords: E75; breast cancer; cancer vaccine; nelipepimut-S; peptide